In this article
For patients whose tumors cannot be surgically removed β due to size, location near major blood vessels, or the presence of multiple metastatic lesions β a combination of minimally invasive approaches has shown promise. Argon-helium ultra-cold knife treatment uses physical freezing and thawing to rapidly destroy tumor cell structures and promote necrosis while closing small tumor blood vessels. When combined with interventional therapy β which embolizes larger tumor vessels and delivers high-concentration chemotherapy locally β the two approaches work together to inhibit liver cancer cell growth and eliminate tumor lesions in a shorter period of time.
CIK (cytokine-induced killer) cells are mononuclear cells isolated from peripheral blood, bone marrow, or umbilical cord blood, expanded in the laboratory, and then reinfused into the patient. They work by directly killing tumor cells in the blood and lymph, while also restoring the patient's immune function to better identify and destroy remaining cancer cells β helping to prevent further spread and metastasis.
Clinical data from 9 patients with stage 4 liver cancer who underwent more than 3 cycles of CIK cell immunotherapy after surgery showed an average survival time of 20 months post-treatment, with a recurrence rate of only 22.2% within the first year β significantly lower than the 60% seen with conventional treatment alone. Most patients also reported improvement in discomfort symptoms. For patients seeking to reduce recurrence risk and improve quality of life after liver cancer treatment, cell immunotherapy represents a meaningful and increasingly viable option.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
β Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.